{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T17:14:35Z","timestamp":1720199675538},"reference-count":20,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2024,2,29]]},"DOI":"10.5582\/ddt.2023.01091","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T22:11:25Z","timestamp":1708467085000},"page":"71-74","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of the physicochemical properties of branded and generic glucose-added maintenance hypotonic infusion fluids to assess the potential for phlebitis and incompatibility with other drugs"],"prefix":"10.5582","volume":"18","author":[{"given":"Sawako","family":"Takei","sequence":"first","affiliation":[{"name":"Center for Experimental Pharmacy Practice, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soh","family":"Katsuyama","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacy, Nihon Pharmaceutical University, Saitama, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Hori","sequence":"additional","affiliation":[{"name":"Center for Experimental Pharmacy Practice, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","unstructured":"1. Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare. Instructions for Package Inserts of Prescription Drugs, PSEHB Notification No.0608-1 June 8, 2017. <i>https:\/\/www.phrma-jp.org\/wordpress\/wp-content\/uploads\/2019\/05\/PSEHB-Notification-No.0608-1_E_1.1.pdf<\/i> (accessed February 10, 2024)."},{"key":"2","unstructured":"2. Sugiura S. Acidosis caused by high-calorie infusion. Pharmaceuticals. 1998; 40:1096-1102."},{"key":"3","unstructured":"3. Ishii I, Suzuki T, Takahashi H, <i>et al<\/i>. Chushayakuchozai Kansamanyuaru 2021 (Ishii I, ed.). Elsevier Japan, Tokyo, Japan, 2020; pp. 1-806."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kuwahara T, Asanami S, Kawauchi Y, Kubo S. Experimental infusion phlebitis: tolerance pH of peripheral vein. J Toxicol Sci. 1999; 24:113-121.","DOI":"10.2131\/jts.24.113"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Manrique-Rodr\u00edguez S, Heras-Hidalgo I, Pernia-L\u00f3pez MS, <i>et al<\/i>. Standardization and chemical characterization of intravenous therapy in adult patients: A step further in medication safety. Drugs R D. 2021; 21:39-64.","DOI":"10.1007\/s40268-020-00329-w"},{"key":"6","unstructured":"6. Okamura K, Nagamoto N, Kume S, Osako T, Nomura K, Ogasawara K. The effect of pH and titratable acidity of infusion solutions on thrombophlebitis during peripheral parenteral nutrition. Jpn J Surg Metab Nutr. 1998; 32:303-308."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kuwahara T, Asanami S, Tamura T, Kubo S. Experimental infusion phlebitis: importance of titratable acidity on phlebitic potential of infusion solution. Clin Nutr. 1996; 15:129-132.","DOI":"10.1016\/S0261-5614(96)80037-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Gazitua R, Wilson K, Bistrian BR, Blackburn GL. Factors determining peripheral vein tolerance to amino acid infusions. Arch Surg. 1979; 114:897-900.","DOI":"10.1001\/archsurg.1979.01370320029005"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kuwahara T, Asanami S, Kubo S. Experimental infusion phlebitis: Tolerance osmolality of peripheral venous endothelial cells. Nutrition. 1998; 14:496-501.","DOI":"10.1016\/S0899-9007(98)00037-9"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Pittiruti M, Hamilton H, Biffi R, MacFie J, Pertkiewicz M, Espen. ESPEN Guidelines on Parenteral Nutrition: central venous catheters (access, care, diagnosis, and therapy of complications). Clin Nutr. 2009; 28:365-377.","DOI":"10.1016\/j.clnu.2009.03.015"},{"key":"11","unstructured":"11. Takei S, Ohara H, Kageyama M, Tobari H, Besshoh S, Hamada M, Inoue M, Samizo K, Kuramoto K. Investigation into the physicochemical quality of original and generic infusion fluid preparation (1). J Drug Interact Res. 2016; 39:135-144."},{"key":"12","unstructured":"12. Takei S, Ohara H, Kageyama M, Tobari H, Besshoh S, Hamada M, Masuda T, Ohyama K, Katsuyama S, Inoue M, Kuramoto K. Investigation into the physicochemical quality of original and generic infusion fluid preparations (2): Investigation on the maintenance fluid (No.3). Jpn Soc Clin Info Parenteral Drugs. 2017; 6:25-35."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Takei S, Katsuyama S, Hori Y. Physicochemical properties of brand and generic infusion fluid preparations (Part 3): Investigation of type 1 hypotonic infusion fluids. Drug Discov Ther. 2021; 15:241-247.","DOI":"10.5582\/ddt.2021.01083"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Takei S, Katsuyama S, Hori Y. Physicochemical properties of branded and generic infusion fluid preparations: Results of a comparative experimental study on type 2 hypotonic infusion fluid. Yakugaku Zasshi. 2023; 143:471-476.","DOI":"10.1248\/yakushi.22-00192"},{"key":"15","unstructured":"15. Terumo Corporation. KCL Injection20mEq package insert. <i>https:\/\/www.terumo.co.jp\/medical\/infusionfluid\/upload_files\/470034_3319402G3028_1_05.pdf<\/i> (accessed February 10, 2024)."},{"key":"16","unstructured":"16. Terumo Corporation. SOLDEM3AG, SOLDEM3PG Interview Form. <i>https:\/\/www.terumo.co.jp\/medical\/infusionfluid\/upload_files\/sol_if.pdf<\/i> (accessed February 10, 2024)."},{"key":"17","unstructured":"17. e-Stat. National Health and Nutrition Examination Survey14 Mean and Standard Deviation of Height and Weight Statistical Tables and Graphs |General Contact of Government Statistics. <i>https:\/\/www.e-stat.go.jp\/dbview?sid=0003224177<\/i> (accessed February 10, 2024)."},{"key":"18","unstructured":"18. Otsuka M. Infusion Management of Severely Asthmatic Patients. In: Infusion Management Q&amp;A 2nd Edition. (Okamoto K, ed). Sogo Igaku Sha, Co., Ltd. Tokyo, Japan, 2012; pp.152-158. (in Japanese)"},{"key":"19","unstructured":"19. Sanofi K.K. Bisolvon<sup>\u00ae<\/sup> Injection 4mg interview form. <i>https:\/\/www.e-mr.sanofi.co.jp\/dam\/jcr:85ea8c04-145e-4abb-b8d3-af79f9e15f23\/bisolvon_inj.pdf<\/i> (accessed February 10, 2024)."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kuwahara T, Asanami S, Tamura T, Kubo S. Experimental infusion phlebitis: importance of titratable acidity on phlebitic potential of infusion solution. Clin Nutr. 1996; 15:129-132.","DOI":"10.1016\/S0261-5614(96)80037-9"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/18\/1\/18_2023.01091\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T04:21:03Z","timestamp":1711167663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/18\/1\/18_2023.01091\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2023.01091","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]},"article-number":"2023.01091"}}